Published in N Engl J Med on June 15, 2000
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am (2013) 2.29
Central role of the P2Y12 receptor in platelet activation. J Clin Invest (2004) 1.96
Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol (2008) 1.69
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ (2000) 1.36
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Thrombotic thrombocytopenic purpura and clopidogrel--a need for new approaches to drug safety. N Engl J Med (2000) 1.30
An update on the first decade of the European centralized procedure: how many innovative drugs? Br J Clin Pharmacol (2006) 1.23
Future innovations in anti-platelet therapies. Br J Pharmacol (2008) 1.13
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.06
Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am (2007) 1.03
ADP and platelets: the end of the beginning. J Clin Invest (2001) 1.01
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl (2009) 1.00
A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci U S A (2002) 0.99
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol (2007) 0.97
Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf (2013) 0.94
Acquired haemophilia A may be associated with clopidogrel. BMJ (2004) 0.91
Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterr J Hematol Infect Dis (2010) 0.85
The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Res (2008) 0.85
Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy (2004) 0.85
Managing adverse effects and drug-drug interactions of antiplatelet agents. Nat Rev Cardiol (2011) 0.84
A patient with acquired hemophilia A induced by clopidogrel. Korean J Hematol (2012) 0.83
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura. Heart (2005) 0.83
ADAMTS13 and microvascular thrombosis. Expert Rev Cardiovasc Ther (2006) 0.82
Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? Curr Control Trials Cardiovasc Med (2000) 0.80
Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. Pediatr Nephrol (2008) 0.79
Profound thrombocytopenia after primary exposure to eptifibatide. Drug Healthc Patient Saf (2010) 0.79
Clopidogrel and thrombotic thrombocytopenic purpura. N Engl J Med (2000) 0.78
Thrombotic thrombocytopenic purpura: survival by "giving a dam". Trans Am Clin Climatol Assoc (2004) 0.78
Recurrent thrombotic thrombocytopenic purpura-like syndrome as a paraneoplastic phenomenon in malignant peritoneal mesothelioma: a case report and review of the literature. Case Rep Oncol Med (2012) 0.78
Antithrombotic Secondary Prevention After Stroke. Curr Treat Options Cardiovasc Med (2002) 0.77
Thrombotic Thrombocytopenic Purpura associated with Clopidogrel: a case report and review of the literature. J Res Med Sci (2011) 0.77
Clopidogrel and thrombotic thrombocytopenic purpura. N Engl J Med (2000) 0.77
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction. Vasc Health Risk Manag (2010) 0.77
Risk reduction with clopidogrel in the management of peripheral arterial disease. Vasc Health Risk Manag (2007) 0.76
Use of antiplatelet inhibitors in peripheral vascular interventions. Semin Intervent Radiol (2005) 0.75
Is clopidogrel superior to aspirin in secondary prevention of vascular disease? Curr Control Trials Cardiovasc Med (2000) 0.75
Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura following Endovascular Treatment of Spontaneous Carotid Artery Dissection. J Neurol Surg Rep (2015) 0.75
Noncardiogenic pulmonary edema associated with clopidogrel: a serious but unexpected side effect of clopidogrel. Can J Cardiol (2007) 0.75
Low ADAMTS-13 in plavix induced thrombotic thrombocytopenic purpura. World J Clin Cases (2013) 0.75
Work up for the clopidogrel hypersensitivity that led to recognising the undiagnosed myelodysplastic syndrome. J Geriatr Cardiol (2016) 0.75
Clopidogrel and thrombotic thrombocytopenic purpura. N Engl J Med (2000) 0.75
Pernicious Anemia Associated Cobalamin Deficiency and Thrombotic Microangiopathy: Case Report and Review of the Literature. Case Rep Med (2017) 0.75
Acute serious thrombocytopenia associated with intracoronary tirofiban use for primary angioplasty. Case Rep Med (2014) 0.75
Complete recovery of ischemic cardiomyopathy from thrombotic thrombocytopenic purpura. Clin Med Insights Cardiol (2011) 0.75
Clopidogrel and thrombotic thrombocytopenic purpura. N Engl J Med (2000) 0.75
Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes. Patient Relat Outcome Meas (2010) 0.75
Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases. Heart (2004) 0.75
The effect of in-hospital acquired thrombocytopenia on the outcome of patients with acute coronary syndromes: A systematic review and meta-analysis. Thromb Res (2016) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature (2001) 6.95
Platelets and shear stress. Blood (1996) 4.18
Bartonella-like erythrocyte inclusions in thrombotic thrombocytopenic purpura. Lancet (1997) 4.09
Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med (1982) 4.05
Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res (1987) 3.86
Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) (1977) 3.20
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood (1999) 2.95
Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA (1997) 2.93
Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med (1972) 2.79
Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol (1988) 2.60
Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood (1997) 2.58
Therapeutic defibrination in the treatment of thrombotic disease. Lancet (1968) 2.40
The nephrotic syndrome associated with secondary syphilis. An immune deposit disease. Am J Med (1970) 2.37
Tumor promoters block tyrosine-specific phosphorylation of the epidermal growth factor receptor. Proc Natl Acad Sci U S A (1984) 2.28
Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest (1986) 2.28
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol (2004) 2.23
A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol (2006) 2.12
Myonecrosis after revascularization procedures. J Am Coll Cardiol (1998) 2.11
Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation (2001) 2.05
Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia (2007) 2.03
Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation (2001) 2.03
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med (1985) 1.97
Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma (2000) 1.94
A comparative analysis of pulmonary perfusion scans with pulmonary angiograms. Am Heart J (1976) 1.93
Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol (1992) 1.92
Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) (1981) 1.88
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood (1997) 1.85
Current concepts: guidelines for the use of thrombolytic agents. N Engl J Med (1979) 1.82
Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol (1978) 1.79
Mucoid degeneration of heart valves: "blue valve syndrome". Am J Clin Pathol (1970) 1.78
Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation (1987) 1.78
The clinical features of submassive and massive pulmonary emboli. Am J Med (1977) 1.77
Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood (2000) 1.77
Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions. J Thromb Haemost (2008) 1.68
Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol (2005) 1.67
Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apher (2004) 1.65
Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol (1989) 1.64
Letter: Dilantin, agranulocytosis, and phagocytic marrow histiocytes. Ann Intern Med (1976) 1.63
Myocardial contrast echocardiography can be used to quantify intramyocardial blood volume: new insights into structural mechanisms of coronary autoregulation. Circulation (1997) 1.63
Disulfide bond reduction of von Willebrand factor by ADAMTS-13. J Thromb Haemost (2010) 1.59
Disseminated intravascular coagulation and portal hypertension following pancreatic islet autotransplantation. Ann Surg (1980) 1.58
Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood (1987) 1.57
In-hospital and long-term outcomes of patients with acute myocardial infarction undergoing direct angioplasty during regular and after hours. J Invasive Cardiol (2001) 1.57
A rapid, effective technique for retrograde crossing of valvular aortic stenosis using standard coronary catheters. Cathet Cardiovasc Diagn (1990) 1.53
Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int (2000) 1.52
Typhoid fever. Studies of blood coagulation, bacteremia, and endotoxemia. Arch Intern Med (1978) 1.52
Estrogen acutely abolishes abnormal cold-induced coronary constriction in men. Chest (1998) 1.49
Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med (2000) 1.48
Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation. Lancet (1999) 1.48
Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann Intern Med (1976) 1.46
Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet (1999) 1.46
Relationship between left ventricular wall thickness and left atrial size: comparison with other measures of diastolic function. J Am Soc Echocardiogr (1995) 1.46
Oxidative damage in age-related macular degeneration. Histol Histopathol (2007) 1.44
Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission. J Pediatr (1992) 1.44
Thrombotic thrombocytopenic purpura and simvastatin. Lancet (1998) 1.44
Bone marrow involvement in T-cell-rich B-cell lymphoma. Am J Clin Pathol (1997) 1.43
Acetaminophen and warfarin: undesirable synergy. JAMA (1998) 1.43
In vivo validation of compensatory enlargement of atherosclerotic coronary arteries. Am J Cardiol (1993) 1.42
von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest (1991) 1.41
In vitro B-mode ultrasonographic criteria for diagnosing axillary lymph node metastasis of breast cancer. J Ultrasound Med (1999) 1.41
Influence of contrast media on thrombus formation during coronary angioplasty. J Am Coll Cardiol (1991) 1.41
Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow. Pharmacogenomics J (2003) 1.41
Philadelphia chromosome in essential thrombocythemia? Am J Hematol (1989) 1.40
t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol (1997) 1.39
Breaking the silence of factitious disorder. South Med J (1998) 1.39
The effect of arvin on blood coagulation factors. Br J Haematol (1968) 1.39
Comparison of immediate and in-hospital results of conventional balloon and perfusion balloon angioplasty using intracoronary ultrasound. Am J Cardiol (1999) 1.39
Changes in left ventricular diastolic performance after aortic balloon valvuloplasty: acute and late effects. J Am Coll Cardiol (1990) 1.38
Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med (1985) 1.38
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol (2009) 1.36
Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood (2001) 1.35
Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology (1985) 1.34
Current status of pulmonary thromboembolic disease: pathophysiology, diagnosis, prevention, and treatment. Am Heart J (1982) 1.34
Neurokinin 3 receptor immunoreactivity in the septal region, preoptic area and hypothalamus of the female sheep: colocalisation in neurokinin B cells of the arcuate nucleus but not in gonadotrophin-releasing hormone neurones. J Neuroendocrinol (2009) 1.33
Lytic anti-endothelial cell antibodies in haemolytic-uraemic syndrome. Lancet (1988) 1.33
Binding and endocytosis of cluster glycosides by rabbit hepatocytes. Evidence for a short-circuit pathway that does not lead to degradation. J Biol Chem (1982) 1.32
Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost (2005) 1.31
von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res (2001) 1.27
Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest (1987) 1.27
Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol (1995) 1.27
Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood (1993) 1.25
Can rifampicin be restarted in patients with rifampicin-induced thrombocytopenia? Tubercle (1991) 1.23
Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood (1992) 1.20
Disorganization of cultured vascular endothelial cell monolayers by fibrinogen fragment D. Science (1985) 1.19
Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am J Hematol (1979) 1.18
Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol (1990) 1.17
Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med (1999) 1.17
Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol (1991) 1.16
Localization of a fibrinogen calcium binding site between gamma-subunit positions 311 and 336 by terbium fluorescence. J Biol Chem (1985) 1.16
Glycogen-rich clear cell carcinoma of the breast: a light and electron microscopic study. Cancer (1981) 1.16
Binding of radioiodinated human von Willebrand factor to Bernard-Soulier, thrombasthenic and von Willebrand's disease platelets. Thromb Res (1981) 1.16
The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med (1979) 1.16
Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med (1989) 1.16
MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol (1985) 1.15